Asian Journal of Research in Chemistry

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Development of Uv Spectrophotometric Method for Estimation of Carvedilol in Bulk and Pharmaceutical formulations


Affiliations
1 Department of Pharmaceutics, KCT’S RGS College of Pharmacy, Anjaneri, Nashik, 422 213. Maharashtra
2 Department of Pharmaceutics, S.M.B.T. College of Pharmacy, Dhamangaon, Nashik, 422 403.Maharashtra
3 Department of Pharmaceutics, Vishnu College of Pharmaceutical Education and Research, Medak, Hyderabad, AP
     

   Subscribe/Renew Journal


A simple, sensitive, highly accurate spectrophotometric method has been developed for the determination of carvedilol in bulk and pharmaceutical formulations. The adequate drug solubility and maximum assay sensitivity was found in methanol. The absorbance of carvedilol was measured at 284 nm in the wavelength range of 200‐350 nm. Beer's law was obeyed in the concentration range of 10-35 μg/mL. The slope, intercept and correlation coefficient were also calculated. The proposed method has been successfully used for the analysis of the drug in pure and its tablet dosage forms. Results of percentage recovery shows that the method was not affected by the presence of common excipients. The method was validated by sensitivity and precision which proves suitability of proposed method for the routine estimation of carvedilol in bulk and pharmaceutical formulations.

Keywords

Carvedilol, UV Spectrophotometric Estimation, Method Development
Subscription Login to verify subscription
User
Notifications
Font Size


  • The Merck Index, Merck and Co., INC Whitehouse station, NJ.2001; 13th edition: pp. 318.

  • Anderson P., Knoben J., Troutman W. Handbook of clinical drug data. McGraw-Hill,New York. 2002; 10th edition: pp. 354-355.

  • Moffat AC., Osselton MD., Widdop B. Clarke’s Analysis of Drugs and Poisons in pharmaceuticals, body fluids and postmortem material. Pharmaceutical Press, London. 2004;3rd edition: pp. 760-761.

  • Flanagan RJ. Guidelines for the interpretation of analytical toxicology results and unit of measurement conversion factors. Ann Clin Biochem. 35(2); . 1998; 261-265.

  • Moser M. Frishman WH. Results of therapy with carvedilol, a - blocker vasodilator with antioxidant properties, in hypertensive patients. Am. J. Hypertens.11; 1998:15S-22S.

  • Martindale, The complete drug reference, Pharmaceutical Press, Great Britain, 2004; 34th edition: pp.881.

  • Tripathi KD, Essentials of Medical Pharmacology, Jaypee Brothers Medical publishers Pvt.Ltd., India. 2002; 5th edition : pp.131.

  • Nicholas AJ, Sulpizio AC, Ashton DJ, Hieble JP, Ruffolo RR. In vitro pharmacologic profile of the novel beta-adrenoreceptor antagonist and vasodialator,carvedilol. Pharmacology.39;1989: 327-336.

  • Ruffolo RR, Gellai M, Hieble JP, Willette RN, Nicholas AJ. The pharmacology of carvedilol. European Journal of Clinical Pharmacology. 38; 1990:S82-88.

  • Nicholas AJ, Gellai M, Ruffolo RR Jr: Studies on the mechanism of arterial vasodialation produced by the novel anti hypertensive agent, carvedilol. Fundamental Clinical Pharmacology. 5; 1991:25-38.

  • Feuerstein GZ, Rufflo RR.Jr: Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. European Heart Journal. 16; 1995:38-42.

  • Sung CP, Arleth AJ, Ohlstein EH. Carvedilol inhibits vascular smooth muscle cell proliferation. Journal of Cardiovascular Pharmacology.2; 1993:221-27.

  • Tenero DM, Henderson LS, Charlotte A, Baidoo MM. Pharmacokinetic properties of a new controlled release carvedilol. The American Journal of Cardiology. 98; 2006:5L- 16L.

  • Kalimuthu S, Yadav AV. Formulation and evaluation of carvedilol loaded Eudragit E 100 nanoparticles. International Journal of Pharm Tech Research.1(2);2009:179-83.

  • McTavish D, Campoli-Richards D, Sorkin EM. Carvedilol: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs.45; 1993:232-58.

  • Chakarborty S, Shukla D, Jain A, Mishra B, Singh S.Assesment of solubilization characteristics of different surfactant for carvedilol phosphate as a function of pH. Journal of Colloid and Interfence Science. 335; 2009:242-49.

  • Mollendorff EV, Reiff K, Neugebauer G. Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker. Eur J Clinical Pharm. 33; 1987:511-513.

  • SubhashiniEdla, Syama SB. RP-HPLC method development and validation for the analyisis of carvedilol in pharmaceutical dosage forms. International Journal of Science Innovations and Discoveries. 1(3); 201: 433-440.

  • Patel LJ, Suhagia BN, Shah PB, Shah RR. RP-HPLC and HPTLC methods for the estimation of carvedilol in bulk drug and pharmaceutical formulations. Indian J. Pharm. Sci.68; 2006: 790-793.

  • Theivarasu C, Santanu Ghosh, Indumathi T. UV spectrophotometric determination of carvedilol in pharmaceutical formulations. Asian Journal of Pharmaceutical and Clinical Research. 3( 4); 2010:64-68

  • Bilal Yilmaz, Sakir Arslan. Determination of Carvedilol in Human Plasma by Gas Chromatography–Mass Spectrometry Method. Journal of Chromatographic Science.49; 201:35-39.

  • VermaJK,Syed HA. Extractive spectrophotometric method for determination carvedilol of tablets. Indian J. Pharm. Sci., 2007,69(2):303-304.

  • Zarghi A., Foroutan SM, Shafaati A, Khoddam A. Quantification of carvedilol in human plasma by liquid chromatography using fluorescence detection: Application in pharmacokinetic studies. J. Pharm. Biomed. Anal.44; 2007:250–253.

  • Galanopoulou, O, Rozou S, Antoniadou-Vyza E. HPLC analysis, isolation and identification of a new degradation product in carvedilol tablets. Journal of Pharmaceutical and Biomedical Analysis. 48(1); 2008:70-77.

  • Suddhasattya D, Dhiraj Kumar SA, Sreenivas D, Sandeep AC. Analytical method development & validation of carvedilol by HPLC in bulk and dosage form. Journal of Pharmacy Research. 3(12); 2010: 3075-3077.

  • Pattana S, Somsak K, Sakawrat T. Development of Carvedilol assay in tablet dosage form using HPLC with fluorescence detection. Maejo Int J Sci Technol. 4(1);2010: 8-19.

  • Q2A: Text on; Validation of Analytical Procedures. In International Conference on Harmonization. Federal Register. 60(40), 1995; 11260–11262.

  • Q2B: Validation of Analytical Procedures: Methodology, Availability. In International Conference on Harmonization. Federal Register. 62(96); 1997; 27463–27467.


Abstract Views: 977

PDF Views: 2




  • Development of Uv Spectrophotometric Method for Estimation of Carvedilol in Bulk and Pharmaceutical formulations

Abstract Views: 977  |  PDF Views: 2

Authors

Shinkar Dattatraya Manohar
Department of Pharmaceutics, KCT’S RGS College of Pharmacy, Anjaneri, Nashik, 422 213. Maharashtra
Dhake Avinash Sridhar
Department of Pharmaceutics, S.M.B.T. College of Pharmacy, Dhamangaon, Nashik, 422 403.Maharashtra
Setty Chitral Mallikarjuna
Department of Pharmaceutics, Vishnu College of Pharmaceutical Education and Research, Medak, Hyderabad, AP

Abstract


A simple, sensitive, highly accurate spectrophotometric method has been developed for the determination of carvedilol in bulk and pharmaceutical formulations. The adequate drug solubility and maximum assay sensitivity was found in methanol. The absorbance of carvedilol was measured at 284 nm in the wavelength range of 200‐350 nm. Beer's law was obeyed in the concentration range of 10-35 μg/mL. The slope, intercept and correlation coefficient were also calculated. The proposed method has been successfully used for the analysis of the drug in pure and its tablet dosage forms. Results of percentage recovery shows that the method was not affected by the presence of common excipients. The method was validated by sensitivity and precision which proves suitability of proposed method for the routine estimation of carvedilol in bulk and pharmaceutical formulations.

Keywords


Carvedilol, UV Spectrophotometric Estimation, Method Development

References